



**HAL**  
open science

## **MELF invasion in endometrial cancer as a risk factor for lymph node metastasis.**

Kitty Pavlakis, Irimi Messini, Theodoros Panoskaltsis, Thomas Vrekoussis,  
Dimitris Chrysanthakis, Petros Yiannou, Zannis Voulgaris

### ► **To cite this version:**

Kitty Pavlakis, Irimi Messini, Theodoros Panoskaltsis, Thomas Vrekoussis, Dimitris Chrysanthakis, et al.. MELF invasion in endometrial cancer as a risk factor for lymph node metastasis.. *Histopathology*, 2011, 58 (5), pp.739. 10.1111/j.1365-2559.2011.03801.x . hal-00626293

**HAL Id: hal-00626293**

**<https://hal.science/hal-00626293>**

Submitted on 25 Sep 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**MELF invasion in endometrial cancer as a risk factor for lymph node metastasis.**

|                               |  |
|-------------------------------|--|
| Journal:                      | <i>Histopathology</i>  |
| Manuscript ID:                | HISTOP-03-10-0175.R2   |
| Wiley - Manuscript type:      | Original Article   |
| Date Submitted by the Author: | 09-Jul-2010  |
| Complete List of Authors:     | Pavlakis, Kitty; "IASO" Women's Hospital, Pathology<br>MESSINI, IRINI; "IASO" Women's Hospital, Pathology<br>Panoskaltzis, Theodoros; "IASO" Women's Hospital, Gynecological Oncology<br>Vrekoussis, Thomas; University of Crete, Pathology<br>Chrysanthakis, Dimitris; "IASO" Women's Hospital, Pathology<br>Yiannou, Petros; "IASO" Women's Hospital, Pathology<br>Voulgaris, Zannis; Alexandra Hospital, National and Kapodistrian University, Gynecological Oncology |
| Keywords:                     | endometrioid endometrial carcinoma,, MELF pattern invasion, lymph node metastasis  |
|                               |  |



1 **MELF invasion in endometrial cancer as a risk factor for**  
2 **lymph node metastasis.**

3 Kitty Pavlakis, MD, PhD <sup>a,b</sup>, Irini Messini, MD <sup>b</sup>, Thomas Vrekoussis, MD,  
4 PhD <sup>c</sup> Theodoros Panoskaltsis MD, PhD <sup>d</sup>, Dimitris Chrysanthakis, MD <sup>b</sup>,  
5 Petros Yiannou, MD <sup>b</sup> and Zannis Voulgaris MD, PhD <sup>e</sup>.

6 <sup>a</sup> Pathology Department, National and Kapodistrian University of Athens, Greece.

7 <sup>b</sup> Pathology Department, "IASO" Women's Hospital, Athens, Greece

8 <sup>c</sup> Pathology Department, University of Crete, Heraklion, Greece

9 <sup>d</sup> Department of Gynecological Oncology, "IASO" Women's Hospital, Athens, Greece

10 <sup>e</sup> Department of Gynecology, Alexandra Hospital, National and Kapodistrian University  
11 of Athens, Greece.

12 **Corresponding author**

13 Kitty Pavlakis, MD

14 Associate Professor of Pathology

15 National and Kapodistrian University of Athens

16 Kyprou 9, Kifissia, 14562

17 Athens – Greece

18 E-Mail: [epavlaki@med.uoa.gr](mailto:epavlaki@med.uoa.gr)

19 Tel: 00302108016714

20 FAX: 00302106185294

21 **Abstract**

22 **Aim:** To investigate whether the microcystic, elongated and fragmented (MELF) pattern  
23 of myometrial invasion encountered in certain endometrioid endometrial carcinomas can  
24 be considered as a risk factor for lymph node metastasis.

25 **Materials and Methods:** 351 cases of total abdominal hysterectomy and bilateral  
26 salpingo-oophorectomy with/without lymphadenectomy or lymph node sampling,  
27 performed for endometrioid endometrial adenocarcinoma were enrolled in the study. The  
28 existence of MELF invasion, vascular invasion, fibromyxoid stromal reaction and lymph  
29 node metastasis were recorded. Immunohistochemistry for endothelial and epithelial  
30 markers was performed on selected cases.

31 **Results:** MELF invasion was identified in 20 (10.81%) and 13 cases (13.13%) treated  
32 without and with lymphadenectomy respectively. All of these cases were either well or  
33 moderately differentiated carcinomas, stage IA to II (without considering lymph node  
34 status). Positive lymph nodes were detected in 7/13 MELF positive (53.84%) and in 6/86  
35 MELF negative cases (6.97%) This observation was statistically significant. Out of the 7  
36 MELF positive tumours with lymph node metastasis, 3 cases exhibited intravascular  
37 tumour emboli while 4 showed a fibromyxoid stromal reaction.

38 **Conclusion:** MELF pattern invasion was found to be statistically related to lymph node  
39 metastasis. Nevertheless, further studies are needed in order to evaluate the clinical  
40 significance of this observation.

41 **Key words:** endometrioid endometrial carcinoma, MELF pattern invasion, lymph node  
42 metastasis.

43 **Introduction**

44 The standard surgical treatment for endometrioid endometrial adenocarcinoma remains  
45 the total abdominal hysterectomy with bilateral salpingo-oophorectomy, whereas there is  
46 controversy concerning the indications for and the type of lymphadenectomy that should  
47 be performed (pelvic and/or para-aortic, systematic or selective)<sup>(1, 2)</sup>. Several studies have  
48 focused on the benefit of lymphadenectomy for patients with Stage IA (former FIGO  
49 1B), grade 1 or 2 endometrial carcinomas. The results of these studies revealed no  
50 survival benefit for the women enrolled in the lymphadenectomy group as opposed to  
51 those without lymphadenectomy<sup>(3, 4, 5)</sup>. Moreover, this group of patients is considered at  
52 low risk for having positive lymph-nodes, since the risk of pelvic recurrences has been  
53 found to range from 0-2%<sup>(6)</sup>.

54 Since lymphadenectomy prolongs the operation time with potential short-term and long-  
55 term side effects, several authors conclude that lymphadenectomy in Stage IA  
56 endometrial carcinoma should only be performed in patients with adenosquamous, serous  
57 or clear cell carcinoma and grade 3 tumours of any histological type<sup>(7)</sup>. For those patients  
58 in whom additional risk factors are revealed in the hysterectomy material, such as deep  
59 myometrial invasion or presence of lymph-vascular tumour emboli, an additional pelvic  
60 radiotherapy is recommended<sup>(8)</sup>.

61 Recently, a distinctive pattern of myometrial invasion has been described under the  
62 “MELF” acronym<sup>(9)</sup>. This microcystic, elongated and fragmented (MELF), pattern of  
63 myometrial invasion has been reported in a small series of three cases to be associated  
64 with a histiocyte-like pattern of lymph node metastasis<sup>(10)</sup>.

65 The aim of the present study was to investigate in a large retrospective analysis of  
66 endometrioid endometrial carcinomas treated with total abdominal hysterectomy,

67 bilateral salpingo-oophorectomy and sampling or systematic pelvic, with or without para-  
68 aortic lymph-node dissection, whether the MELF pattern of myometrial invasion is  
69 related to an increased occurrence of lymph node metastasis and as such, could be  
70 considered as an additional risk factor for advanced stage disease.

## 71 **Materials and Methods**

72 Three hundred and fifty one (351) consecutive unselected cases of endometrioid  
73 endometrial adenocarcinoma operated between Jan. 1998, and Dec. 2009 were retrieved  
74 from the files of the Pathology Department of “IASO” Women’s Hospital. Out of these  
75 cases, only 238 (Group A) had been treated by total abdominal hysterectomy (TAH) and  
76 bilateral salpingo-oophorectomy (BSO), while in 113 cases (Group B) lymph node  
77 sampling or systematic pelvic lymphadenectomy with or without para-aortic lymph node  
78 sampling had also been performed. In 53 Group A cases and 14 Group B cases the  
79 carcinoma was confined to the endometrium, thereafter they were not enrolled in the  
80 study. All cases were classified according to FIGO 2009 staging system <sup>(11)</sup>. **The last**  
81 **three cases, operated in November 2009 were not included in the study, since they**  
82 **represented intraendometrial carcinomas. Thereafter, survival and recurrence status were**  
83 checked on October 2009.

84 The haematoxylin and eosin stained slides of each hysterectomy and lymphadenectomy  
85 specimen were reviewed by two different pathologists of the team (I.M and D.C). The  
86 presence or absence of MELF pattern invasion, vascular space (either lymphatic or blood  
87 vessel) invasion and fibromyxoid stromal reaction was recorded. Moreover, the  
88 morphology of lymph node metastasis, if present, either as a typical gland-forming  
89 adenocarcinoma or as individual intranodal neoplastic cells was evaluated.

90 Immunohistochemical staining with the endothelial marker CD31 for the identification of  
91 tumour emboli was performed on all sections from the myoinvasive tumour in all MELF  
92 cases, while only selected sections exhibiting morphologic features suggestive of vascular  
93 space invasion were immunostained in some MELF negative tumours.  
94 Immunohistochemistry with cytokeratin AE1/AE3 for the search of metastatic neoplastic  
95 cells was performed in all negative lymph nodes.

#### 96 *Immunohistochemistry*

97 Immunohistochemistry was performed using the avidin-biotin complex method. Briefly,  
98 after dehydration in xylol and graded alcohol, sections were exposed to 3% H<sub>2</sub>O<sub>2</sub> for 15  
99 min. After retreatment in a microwave for 15 min, the tissue sections were incubated with  
100 the primary antibodies against CD31 (clone JC/70A, Dako Corp) and AE1/AE3 (Dako)  
101 with 1:40 and 1:100 dilution respectively, at 4<sup>0</sup>C. After overnight incubation, the slides  
102 were treated with biotinylated antimouse IgG as secondary antibody. Reaction was  
103 visualized using an avidin-biotin-peroxidase complex with 3,3' Diaminobenzidine (DAB,  
104 Sigma Chemical Comp.) as a chromogen. Counterstaining was performed with Harris  
105 Haematoxylin. The vascular endothelium and sections from the uterine tumour were used  
106 as positive controls. Negative controls were obtained by omitting the primary antibody.

#### 107 *Statistical analysis*

108 To discriminate significant differences between categorical variables the Fisher exact test  
109 was used. To examine whether the presence of MELF pattern invasion, of tumour emboli  
110 or of a fibromyxoid stromal reaction could act as a predictive factor for lymph node  
111 metastasis, the logistic regression analysis was applied. Any observation when  $p < 0.05$

112 was considered as statistically significant. Statistical analysis was applied on the results  
113 of group B.

#### 114 **Results**

115 Out of the two hundred and eighty four (284)) cases of endometrioid endometrial  
116 carcinomas (185 group A cases and 99 group B cases) that were finally enrolled in the  
117 study, MELF pattern invasion was identified in 20/185 group A (10.81%) and in 13/99  
118 group B cases (13.13%). All of these cases were either well or moderately differentiated  
119 carcinomas, stage IA to II (without considering lymph node status). The myoinvasive  
120 MELF glands were typically forming microcysts or elongated structures lined by cells  
121 with conspicuous eosinophilic cytoplasm, while clusters of detached cells were also  
122 identified (Fig 1).

123 In group B, positive lymph nodes were detected in 7/13 MELF positive cases (53.84%)  
124 and in 6/86 MELF negative cases (6.97%). This observation was statistically significant  
125 (Fisher exact test,  $p = 0.00014$ ). The pattern of metastasis was either in the form of  
126 isolated, discohesive cells or in the form of small pseudopapillary cell clusters that were  
127 identified mostly within the subcapsular and interfollicular sinuses (Fig 2).

128 Additionally, positive lymph nodes were detected in 8/20 cases (40%) and in 5/79 cases  
129 (6.32%) with and without tumour emboli respectively, as well as in 6/29 cases (20.68%)  
130 and in 7/70 cases (10%) with or without fibromyxoid stromal reaction. The former of  
131 these observations was statistically significant (Fisher exact test,  $p = 0.0005$ ) while the  
132 latter was not (Fisher exact test,  $p=0.1352$ ). The clinicopathological features of all cases  
133 are summarized in Table 1.

134 In 7 out of the 20 MELF positive cases belonging to group A, lymph vascular space  
135 invasion was identified, while 8 cases presented a fibromyxoid stromal reaction. Out of  
136 the 7 MELF positive tumours with lymph node metastasis (group B), 3 cases exhibited  
137 intravascular tumour emboli while 4 showed a fibromyxoid stromal reaction.

138 In both groups, all but one of the MELF positive patients with final stage 1A disease  
139 received no further therapy. The remaining patient had a concurrent ovarian carcinoma.  
140 She was treated with radio and chemotherapy but died five years later from her ovarian  
141 cancer. All other patients had been treated either with radiotherapy alone or with radio  
142 and chemotherapy. Five of the patients were lost from follow up (Table 2).

143 Logistic regression analysis, performed on group B, revealed that there is a significantly  
144 increased possibility for an endometrial cancer to be lymph node positive when MELF  
145 pattern invasion [OR=15.55 /  $p < 0.001$ , 95% C.I. (3.88-62.29)] is present, compared to  
146 cases where MELF is absent. Additionally, there is an increased possibility for lymph  
147 node metastasis when tumour emboli are present [OR=9.86 /  $p < 0.001$ , 95% C.I. (2.71-  
148 35.81)], as opposed to cases without tumour emboli. On the other hand, the presence of a  
149 fibromyxoid stromal reaction was not found to be a predictor of lymph node metastasis  
150 [OR=2.34/ $p=0.1662$ ,95% C.I.(0.43-12.64)].

## 151 Discussion

152 The acronym "MELF" (microcystic, elongated, fragmented) has been recently attributed  
153 to an unusual glandular change of myoinvasive endometrioid carcinoma glands,  
154 characterized by the formation of microcysts lined by cells with conspicuous eosinophilic  
155 cytoplasm, elongated structures and clusters of detached cells occasionally associated  
156 with retraction artifact<sup>(9)</sup>. Although it was initially thought that these changes represented

157 a degenerative process, several studies have suggested that MELF changes might  
158 represent a specific tumour-stromal reaction similar to epithelial-mesenchymal  
159 interactions observed in other tumours <sup>(12, 13, 14)</sup>. In that context, MELF pattern of invasion  
160 could be considered as an active rather than a degenerative cellular process.

161 The distinct glandular changes that characterize MELF are often associated with a  
162 fibromyxoid stromal reaction. In a univariate analysis, the presence of a fibromyxoid  
163 stromal reaction has been found to be associated with an adverse effect on the prognosis  
164 of endometrioid carcinomas <sup>(9)</sup>. One could speculate that this particular stroma represents  
165 a “milieu” of decreased resistance favoring the dissemination of neoplastic cells. A  
166 similar explanation has been attributed to vulvar squamous cell carcinomas featuring a  
167 prominent fibromyxoid stromal response and an aggressive clinical behavior <sup>(15)</sup>.

168 In the present study, MELF pattern invasion was found only in well or moderately  
169 differentiated endometrioid endometrial adenocarcinomas, as already mentioned in  
170 previous reports <sup>(9,13)</sup>, and was usually but not always associated with a fibromyxoid  
171 stroma or with vascular space invasion. Nevertheless, to our knowledge, the relation of  
172 MELF pattern invasion and the probability of lymph node metastasis have never been  
173 studied before.

174 Our results indicate that, when MELF pattern invasion is encountered in an endometrioid  
175 endometrial carcinoma, there is a statistically significant chance of concurrent lymph  
176 node metastasis. Most probably, as seen in the present study, this occurrence is at least in  
177 part related to the great frequency of concurrent lymph vascular space invasion or, to a  
178 lesser extent to the observed fibromyxoid stromal reaction. The above finding is  
179 consistent with the results of other investigators who reported an adverse effect on

180 prognosis and a high risk of recurrence in cases of endometrioid endometrial carcinomas  
181 characterized by a fibromyxoid stroma or by vascular space invasion respectively <sup>(9, 16, 17)</sup>.  
182 The morphological and molecular characteristics of the neoplastic cells in areas of MELF  
183 pattern of invasion, characterized by discohesiveness and by a loss, on  
184 immunohistochemistry, of the cell adhesion molecule e-cadherin, as reported by other  
185 investigators <sup>(14)</sup>, could probably be considered as factors leading to an increased  
186 infiltrative ability of these cells and to an enhancement of their metastatic potential.  
187 Of most importance was the constantly observed pattern of lymph node metastasis. It was  
188 either in the form of isolated, discohesive cells or in the form of small pseudopapillary  
189 cell clusters that were identified mostly within the subcapsular and interfollicular sinuses.  
190 In both conditions the cells were of large size, with abundant eosinophilic cytoplasm and  
191 large nuclei while occasionally some intracytoplasmic vacuoles were identified. These  
192 morphological features are the same as the ones encountered in the myoinvasive MELF  
193 pattern. The above neoplastic cells might be confused with sinusoidal histiocytes or with  
194 serous epithelial non-invasive lymph node “implants” respectively. Characteristically, in  
195 one of our cases, the scattered neoplastic cells were identified only after the performance  
196 of immunohistochemistry with the antibody AE1/AE3. The respective lymph node was  
197 initially considered as being free of metastasis.  
198 Our results are in agreement with those of McKenney et al <sup>(10)</sup> who first reported this  
199 subtle pattern of lymph node metastasis. They stated that although the main tumour was a  
200 gland-forming adenocarcinoma, the metastatic cells had similar morphological features  
201 with the cells observed in areas of MELF pattern invasion. Nevertheless, it seems that on  
202 rare occasions, this pattern of lymph node metastasis can also be encountered in

203 conventionally myoinvasive endometrial adenocarcinomas. In one of our cases, both  
204 gland forming and scattered or small pseudopapillary metastatic foci were identified in  
205 some pelvic and one paraaortic lymph node.

206 In conclusion, MELF pattern invasion was found to be statistically related to lymph node  
207 metastasis. Such a distinct myoinvasive pattern should prompt the pathologist to search  
208 for vascular space invasion by performing more sections from the myoinvasive tumour  
209 and/or immunohistochemistry for endothelial markers. Nevertheless, the clinical  
210 significance of this observation is not elucidated. As shown in the present study, MELF  
211 invasion did not worsen the prognosis of the patients since none recurred or died from the  
212 disease. This result is in agreement with Murray et al <sup>(9)</sup> who reported that MELF pattern  
213 invasion alone did not correlate with an adverse outcome. Yet, in our study, most MELF  
214 cases belonging to group A and all MELF cases with positive lymph nodes (group B) had  
215 received adjuvant treatment since they were intermediate and high stage/risk tumours  
216 (>1A). The therapeutic procedure might have obscured the natural history of the disease.  
217 For all stage 1A MELF cases belonging to group A who did well without further therapy,  
218 no solid conclusion can be drawn. These patients might have been lymph node negative.  
219 On the other hand, the pattern of lymph node metastasis in several MELF cases is in the  
220 form of isolated tumour cells/micrometastasis, whose prognostic significance, to our  
221 knowledge, has not been thoroughly studied in endometrial carcinomas.

222 Further studies with larger series of cases are needed in order to decide whether MELF  
223 pattern invasion should be considered as a risk factor for higher stage disease.  
224 Endometrioid endometrial carcinomas treated with TAH and BSO with  
225 lymphadenectomy/lymph node sampling, when featuring MELF pattern invasion should

226 be very carefully examined in order to exclude the presence of lymph node metastasis in  
227 the form of isolated tumour cells. In that context, performing immunohistochemistry with  
228 cytokeratin AE1/AE3 should be considered as a routine diagnostic procedure. However,  
229 as already stated, clinical studies are required in order to determine the significance of  
230 such isolated tumour cells/micrometastasis in MELF cases.

## 231 REFERENCES

- 232 1. Papanikolaou A, Kalogiannidis I, Goutzioulis M, et al. Pelvic lymphadenectomy  
233 as alternative to postoperative radiotherapy in high risk early stage endometrial cancer.  
234 Arch Gynecol Obstet 2006; 274: 91-96.
- 235 2. Mohan DS, Samuels MA, Selim MA, et al. Long-term outcomes of therapeutic  
236 pelvic lymphadenectomy for stage I endometrial adenocarcinoma. Gynecol Oncol 1998;  
237 70:165-71.
- 238 3. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy  
239 vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.  
240 J Natl Cancer Inst 2008; 100:1707-16.
- 241 4. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the  
242 endometrium: survival comparisons of patients with and without pelvic node sampling.  
243 Gynecol Oncol 1995; 56:29-33.
- 244 5. Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective  
245 lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005;  
246 23:3668-75.

- 247 6. Alektiar KM, McKee A, Lin O, et al. The significance of the amount of  
248 myometrial invasion in patients with Stage IB endometrial carcinoma. *Cancer*  
249 2002;95:316-21.
- 250 7. Bottke D, Wiegel T, Kreienberg R, Kurzeder C, Sauer G. Stage IB endometrial  
251 cancer. Does lymphadenectomy replace adjuvant radiotherapy? *Strahlenther Onkol* 2007;  
252 183:600-4.
- 253 8. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or  
254 without adjunctive external pelvic radiation therapy in intermediate risk endometrial  
255 adenocarcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2004; 92:744-  
256 51.
- 257 9. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in  
258 myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated  
259 diagnostic problems, and prognostic significance *Int J Gynecol Pathol* 2003; 22:324-33.
- 260 10. McKenney JK, Kong CS, Longacre TA. Endometrial adenocarcinoma associated  
261 with subtle lymph-vascular space invasion and lymph node metastasis: a histologic  
262 pattern mimicking intravascular and sinusoidal histiocytes. *Int J Gynecol Pathol* 2005;  
263 24:73-8.
- 264 11. Mutch DG. The new FIGO staging system for cancers of the vulva, cervix,  
265 endometrium and sarcomas. *Gynecol Oncol* 2009; 115:325-328.
- 266 12. Stewart CJ, Crook ML, Leung YC, Platten M. Expression of cell cycle  
267 regulatory proteins in endometrial adenocarcinoma: variations in conventional tumour  
268 areas and in microcystic, elongated and fragmented glands. *Mod Pathol* 2009; 22:725-33.

- 269 13. Stewart CJ, Brennan BA, Leung YC, Little L. MELF pattern invasion in  
270 endometrial carcinoma: association with low grade, myoinvasive endometrioid tumours,  
271 focal mucinous differentiation and vascular invasion. *Pathology* 2009; 41:454-9.
- 272 14. Stewart CJ, Little L. Immunophenotypic features of MELF pattern invasion in  
273 endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition.  
274 *Histopathology* 2009; 55: 91-101.
- 275 15. Ambros RA, Malfetano JH, Mihm MC Jr. Clinicopathologic features of vulvar  
276 squamous cell carcinomas exhibiting prominent fibromyxoid stromal response. *Int J*  
277 *Gynecol Pathol* 1996; 15:137-45.
- 278 16. Alexander-Sefre F, Nibbs R, Rafferty T, et al. Clinical value of  
279 immunohistochemically detected lymphatic and vascular invasions in clinically staged  
280 endometrioid endometrial cancer. *Int J Gynecol Cancer* 2009; 19:1074-9
- 281 17. Narayan K, Rejeki V, Herschtal A et al. Prognostic significance of several  
282 histological features in intermediate and high-risk endometrial cancer patients treated  
283 with curative intent using surgery and adjuvant radiotherapy. *J Med Imaging Radiat*  
284 *Oncol* 2009; 53: 107-13.

285 Figures legends

286 Figure 1: A, C and E. Morphology of MELF pattern invasion (H&E, CD31 and AE1/AE3  
287 respectively, X 100). B, D and F. Lymph vascular space invasion (H&E, CD31 and  
288 AE1/AE3 respectively, X 200).

289 Figure 2:A. Isolated tumor cells of large size and eosinophilic cytoplasm are infiltrating a  
290 lymph node (H&E X 100). B. The neoplastic cells are highlighted with keratin  
291 AE1/AE3 (X100).


**Table 1** Clinicopathological feature of the cases that were enrolled in the study.

| Clinicopathological features        | Group A (%)<br>n=185 | Group B (%)<br>n=99 |        |           |
|-------------------------------------|----------------------|---------------------|--------|-----------|
|                                     |                      | LN (-)              | LN (+) | Total     |
| <b>Grade</b>                        |                      |                     |        |           |
| 1                                   | 80 (43,2)            | 43                  | 2      | 45 (45.5) |
| 2                                   | 74 (40)              | 28                  | 7      | 35 (35.3) |
| 3                                   | 31 (16,8)            | 15                  | 4      | 19 (19.2) |
| <b>Stage</b>                        |                      |                     |        |           |
| IA                                  | 113 (61,1)           | 55                  | -      | 55 (55,6) |
| IB                                  | 57 (30,8)            | 14                  | -      | 14 (14,1) |
| II                                  | 9 (4,9)              | 14                  | -      | 14 (14,1) |
| IIIA                                | 6 (3,2)              | 3                   | -      | 3 (3,0)   |
| IIIC1                               | N/A                  | -                   | 11     | 11 (11,1) |
| IIIC2                               | N/A                  | -                   | 2      | 2 (2,0)   |
| <b>M.E.L.F</b>                      |                      |                     |        |           |
| Yes                                 | 20 (10,8)            | 6                   | 7      | 13 (13,1) |
| No                                  | 165 (89,2)           | 80                  | 6      | 86 (86,9) |
| <b>Vascular space invasion</b>      |                      |                     |        |           |
| Yes                                 | 18 (9,7)             | 12                  | 8      | 20 (20,2) |
| No                                  | 167 (90,3)           | 74                  | 5      | 79 (79,8) |
| <b>Fibromyxoid stromal reaction</b> |                      |                     |        |           |
| Yes                                 | 11 (5,9)             | 23                  | 6      | 29 (29,3) |
| No                                  | 174 (94,1)           | 63                  | 7      | 70 (70,7) |


**Table 2.** Clinicopathologic features of all MELF positive cases

| <i>Case No</i> | <i>Grade</i> | <i>Stage</i>           | <i>Lymph node metastasis</i> | <i>Vascular space invasion</i> | <i>Fibromyxoid Stromal reaction</i> | <i>Adjuvant treatment</i> | <i>Outcome</i>    |
|----------------|--------------|------------------------|------------------------------|--------------------------------|-------------------------------------|---------------------------|-------------------|
| <b>Group A</b> |              |                        |                              |                                |                                     |                           |                   |
| 1              | 1            | IB                     | N / A                        | +                              | +                                   | R                         | Alive             |
| 2              | 2            | IA                     | N / A                        | -                              | -                                   | R & C                     | Dead <sup>1</sup> |
| 3              | 1            | IA                     | N / A                        | -                              | +                                   | No                        | Alive             |
| 4              | 2            | IB                     | N / A                        | +                              | -                                   | R                         | Lost from FU      |
| 5              | 1            | IB                     | N / A                        | -                              | -                                   | R                         | Alive             |
| 6              | 1            | IA                     | N / A                        | -                              | +                                   | No                        | Alive             |
| 7              | 1            | IB                     | N / A                        | +                              | +                                   | R                         | Alive             |
| 8              | 2            | IA                     | N / A                        | -                              | -                                   | No                        | Alive             |
| 9              | 2            | IA                     | N / A                        | -                              | -                                   | No                        | Alive             |
| 10             | 2            | IA                     | N / A                        | -                              | -                                   | No                        | Alive             |
| 11             | 2            | IB                     | N / A                        | +                              | +                                   | R                         | Alive             |
| 12             | 2            | IB                     | N / A                        | +                              | -                                   | R                         | Lost from FU      |
| 13             | 1            | IA                     | N / A                        | -                              | +                                   | No                        | Alive             |
| 14             | 2            | IB                     | N / A                        | +                              | -                                   | R                         | Alive             |
| 15             | 1            | IB                     | N / A                        | -                              | -                                   | R                         | Alive             |
| 16             | 1            | IB                     | N / A                        | -                              | +                                   | R                         | Lost from FU      |
| 17             | 1            | IA                     | N / A                        | -                              | -                                   | No                        | Alive             |
| 18             | 2            | IA                     | N / A                        | -                              | -                                   | No                        | Alive             |
| 19             | 2            | IA                     | N / A                        | -                              | -                                   | No                        | Alive             |
| 20             | 2            | IB                     | N / A                        | +                              | +                                   | R                         | Alive             |
| <b>Group B</b> |              |                        |                              |                                |                                     |                           |                   |
| 1              | 2            | IA <sup>2</sup> /IIIC2 | +                            | -                              | +                                   | R & C                     | alive             |
| 2              | 2            | IA <sup>2</sup> /IIIC1 | +                            | -                              | -                                   | R & C                     | alive             |
| 3              | 2            | IB                     | -                            | -                              | +                                   | R                         | alive             |
| 4              | 1            | IA                     | -                            | -                              | +                                   | No                        | alive             |
| 5              | 1            | II                     | -                            | -                              | +                                   | R                         | Lost from FU      |
| 6              | 1            | IA                     | -                            | -                              | -                                   | No                        | alive             |
| 7              | 1            | IA <sup>2</sup> /IIIC1 | +                            | -                              | -                                   | R                         | alive             |
| 8              | 2            | II <sup>2</sup> /IIIC1 | +                            | +                              | +                                   | R & C                     | alive             |
| 9              | 2            | II <sup>2</sup> /IIIC1 | +                            | +                              | +                                   | R & C                     | alive             |
| 10             | 2            | IA <sup>2</sup> /IIIC1 | +                            | -                              | -                                   | R                         | Lost from FU      |
| 11             | 1            | IB                     | -                            | -                              | +                                   | R                         | alive             |
| 12             | 1            | IA                     | -                            | -                              | -                                   | No                        | alive             |
| 13             | 1            | IA <sup>2</sup> /IIIC1 | +                            | +                              | +                                   | R                         | alive             |

<sup>1</sup> died but not from the disease, <sup>2</sup> stage without considering lymph node status, R: Radiotherapy, C: Chemotherapy



156x175mm (150 x 150 DPI)



149x98mm (150 x 150 DPI)

Review

**To:** Histopathology,  
Editorial-Production Office  
Maura MacDonald

Dear Sirs

I am sending you our manuscript entitled "MELF invasion in endometrial cancer as a risk factor for lymph node metastasis", by Kitty Pavlakis, MD, Iriini Messini, Thomas Vrekoussis, Theodoros Panoskaltsis, Dimitris Chrysanthakis, Petros Yiannou, and Zannis Voulgaris.

We would like it to be considered for publication in Histopathology. The work is original and has not been and will not be published, in part or in whole, in any other journal. All authors have agreed to the contents of the manuscript in its submitted form and declare that they have no conflicts of interest for it.

Thank you in advance for considering our work,

Sincerely  
Iriini Messini, MD.